TP53 mutations and aberrant RAS pathway activity (NRAS, KRAS, PTPN11, NF1) are common features of trAML (27), as well as of EVI1-rearranged (EVI-r) AML (28, 29). Here, RUNX1 is linked to acute myeloid leukemia.